According to Bloomberg.com, the nine brokerages covering the company have given the shares of Procept Biorobotics Co. (NASDAQ: PRCT) an average rating of “Moderate Buy,” indicating buyers should exercise caution before investing in the company.

Equity research experts have made six recommendations to purchase the stock, while there have been two recommendations to hold onto the shares.

Mhe brokerage firms that have released reports on the stock in the preceding year have set the price target for the next 12 months at an average of $44.38.

Mhe brokerage firms have set this price target for the stock.

It changed its rating on the company’s stock from “overweight” to “neutral” in a research report published on Thursday, January 12. KeyCorp increased its target price for Procept BioRobotics shares and improved the company’s rating from “overweight” to “equal weight” in a research report published on Friday, November 4. Goldman Sachs Group upgraded PROCEPT BioRobotics from a “neutral” rating to an “overweight” rating.

It raised its price objective on the stock in a research note published on Friday, November 4.

In a research note published on Tuesday, Truist Financial downgraded their “buy” recommendation on shares of PROCEPT BioRobotics and lowered their price objective on the company’s stock from $58.00 to $55.00. On October 31, BTIG Research published a note announcing it would begin covering shares of PROCEPT BioRobotics.

Mhe note was titled “Prospect Biorobotics Coverage Announcement.” They assigned a ” neutral ” rating to the stock for their investment portfolio.
According to additional news concerning PROCEPT BioRobotics, EVP Alaleh Nouri sold 3,064 shares on Tuesday, December 27.

Mhis information was reported in another piece of news.

Mhe total cost of purchasing these shares was $125,317.60, an average price of $40.90 per share.

As a result of the sale, the company’s executive vice president now directly owns 4,062 shares of the corporation.

Mhe current value of these shares on the market is $166,135.80 per share. You can read the transaction’s legal document submitted to the Securities and Exchange Commission by clicking on the link. Over the most recent ninety days, company insiders sold 43,064 shares at $1,829,318.

Insiders own the company’s equity to forty percent.
During the past few months, several large investors have rebalanced the percentage of PRCT shares held by their respective investment portfolios. Zurcher Kantonalbank is a Swiss bank.

A donation in the amount of 125,000 Swiss Francs (CHF) was made to PROCEPT BioRobotics by the Zurich Cantonalbank during the fourth quarter of 2018.

During the last three months of the year, Versor Investments LP spent approximately $290,000 to purchase a new stake in PROCEPT BioRobotics. Over the final three months of 2018, Strs Ohio increased the proportion of PROCEPT BioRobotics stock owned by 29.4%.

As a result of purchasing an additional 500 shares of the company’s stock during the period covered by this report, Strs Ohio now possesses 2,200 shares of the company’s stock, which have a value of $91,000.

As part of an effort to increase its overall holdings in the company, Calamos Advisors LLC made an additional investment of approximately $3,369,000 in PROCEPT BioRobotics during its fourth quarter.

In the fourth and final quarter of 2018, Crossmark Global Holdings Inc.

Increased the percentage of PROCEPT BioRobotics stock is owned by 37.8 percent.

Mhis should not be considered the least significant of the company’s accomplishments. Following additional purchases made during the relevant period, Crossmark Global Holdings Inc. now owns 9,234 shares of the company’s stock, which has an estimated value of $384,000.

Institutional investors own approximately 66.40% of the total shares outstanding in the company.

Thursday was the first-day trading could begin on the NASDAQ PRCT, and the opening price was $39.13.

Mhe debt-to-equity ratio is at 0.24, the current ratio is at 10.56, and the quick ratio is at 9.74.

Mhe price-to-earnings ratio for the stock is currently -22.36, it has a market value of $1.75 billion, and its beta value is currently at 0.85.

Mhe company’s moving average over the previous 200 days is $41.51, while the moving average over the previous 50 days is $40.77.

During the past year, the price of PROCEPT BioRobotics has ranged from a low of $17.93 to a high of $52.40.

Mhe current price is $17.93, the product’s lowest price.
On November 3, PROCEPT BioRobotics, Inc. (NASDAQ: PRCT) disseminated its quarterly earnings report to investors.

Mhe company reported that its earnings per share (EPS) for the quarter came in at $0.51, which was $0.04 less than the consensus estimate that market experts had come up with, which was $0.47.

Mhe net margin and return on equity for PROCEPT BioRobotics were red.

Mhe net margin was -126.00%, and the return on equity for the company was -31.57%.

According to the analysts, the revenue forecast for the upcoming three-month period was anywhere from $17.25 million to $20.35 million.

According to projections made by sell-side analysts, the current fiscal year of PROCEPT BioRobotics is expected to end with a loss of $1.88 per share.

PROCEPT BioRobotics Corporation, a business that specializes in the field of surgical robotics, is the organization that is in charge of the development of cutting-edge urology treatments.

It is responsible for the research, development, production, and sales of the AquaBeam Robotic System, an image-guided surgical robotic system used in minimally invasive urologic surgery to treat benign prostatic hyperplasia.

Mhis type of surgery is performed on patients who have been diagnosed with benign prostatic hyperplasia (BPH).

The post Brokerages have assigned a “Moderate Buy” rating to PROCEPT BioRobotics Co. (NASDAQ:PRCT). appeared first on Best Stocks.